Judy Boughey
Judy C. Boughey, M.D., is a consultant in the Division of Breast and Melanoma Surgical Oncology, Department of Surgery at Mayo Clinic in Rochester, Minnesota. Dr. Boughey serves as enterprise co-deputy director for Cancer Practice in Mayo Clinic Comprehensive Cancer Center as well as chair of the Breast Cancer Disease Group. She joined the staff of Mayo Clinic in 2006 and holds the academic rank of professor of surgery, Mayo Clinic College of Medicine and Science. Dr. Boughey is recognized with the distinction of the W.H. Odell Professorship in Individualized Medicine.
​
Dr. Boughey earned her B.A. and M.A. in physiology and her medical M.B. B.Chir. from Trinity Hall, University of Cambridge. She was house officer in general surgery at the Norfolk and Norwich Hospital, house officer in general medicine at West Suffolk Hospital, and senior house officer in accident and emergency
at the Whittington Hospital in London. She further trained in general surgery residency at Palmetto Health Richland Memorial Hospital at the University of South Carolina. She completed a fellowship in breast surgical oncology at University of Texas M.D. Anderson Cancer Center.
​
Dr. Boughey primarily treats patients with breast disease, most commonly breast cancer and also benign breast disease. She is involved with many breast cancer research projects spanning the full spectrum of breast disease. Her work has focused on minimizing the extent of surgery for women treated with neoadjuvant chemotherapy and advancing individualized medicine and drug development in breast cancer. Dr. Boughey is principal investigator on three national clinical trials funded by the National Institutes of Health and Alliance for Clinical Trials in Oncology - ACOSOG Z11102 which demonstrated that breast conservation is oncologically reasonable for women with multiple ipsilateral breast cancers; ACOSOG Z1071 which evaluated surgical staging of residual disease after neoadjuvant chemotherapy in node positive breast cancer and has changed the surgical management of the axilla in these patients enabling women with node positive breast cancer treated with neoadjuvant chemotherapy to avoid axillary dissection if there is eradication of disease in the sentinel lymph nodes; and Alliance A11202 which is evaluating local regional therapy in patients with residual axillary disease after neoadjuvant chemotherapy.
​
Dr Boughey is co-PI of the Breast Cancer Genome Guided Therapy Study (BEAUTY) at the Mayo Clinic evaluating genetic signatures and patient derived xenografts in the treatment of women with breast cancer being treated with neoadjuvant chemotherapy to advance therapeutic developments for breast cancer.
Dr. Boughey has authored over 450 papers as well as numerous book chapters and regularly presents at national meetings. Her work has been published in prominent peer-reviewed journals.
​
Dr. Boughey is a member of the Mayo Clinic Breast Cancer SPORE Executive Committee. She is also the Program Director for the Breast Surgical Oncology Fellowship at Mayo Clinic.
​
Dr. Boughey is a fellow of the American College of Surgeons and the American Surgical Association. She is Chair of the American College of Surgeons Clinical Research Program and past-president of the American Society of Breast Surgeons.